
    
      This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter,
      efficacy and safety trial of 12 weeks of treatment with nebulized SUN-101 using an
      Investigational eFlowÂ® Closed System (CS) nebulizer in approximately 645 subjects with
      chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic
      Obstructive Lung Disease (GOLD 2014) guidelines.

      SUN-101 or placebo will be administered twice daily as an oral inhalation using the
      investigational eFlow CS nebulizer.
    
  